Company intelligence / Profile preview

Inivata

Cambridge, Cambridgeshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

Inivata's InVisionFirst-Lung test is commercially available internationally and in the US, offering best-in-class sensitivity for genomic characterization of advanced non-small cell lung cancer. RaDaR, its personalized assay for minimal residual disease (MRD), has US FDA Breakthrough Device Designation and is in several ongoing clinical collaborations for MRD and recurrence monitoring in early and advanced cancers.

Therapeutic areas: Oncology
Modalities: DeviceDiagnosticsLiquid biopsy
Industry: Molecular Diagnostics

Partnerships

Agendia (RaDaR commercial partnership in breast cancer)Princess Margaret Cancer Center (clinical collaboration)Pharmaceutical and biotech company partnerships for clinical development

Beyond the preview

Go deeper on Inivata.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inivata.

Explore the full profile